Viatris Analyst Price Targets - Benzinga

SPY769.95+0.04%QQQ722.18+0.13%BTC/USD81,002.00+0.24%DIA523.52+0.05%GLD372.26−0.01%TLT81.52−0.13%

Premium Services

Viatris Inc

VTRSNASDAQ

Trade with Public

Trade with Public

$18.72

0.432.35%

Last update: Oct 27, 6:40 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Viatris Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viatris (VTRS).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

7Buy

3Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$17Upside to Avg. PT-8.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 26, 2026	Piper Sandler	David Amsellem	PT Raise	Neutral	$13→$14
Oct 21, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$18→$20
Oct 5, 2026	UBS	Ashwani Verma	PT Raise	Buy	$23→$26
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$25
Sep 16, 2026	Piper Sandler	David Amsellem	PT Raise	Neutral	$12→$13
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$20
Sep 8, 2026	Argus Research	Jasper Hellweg	PT Raise	Buy	$15→$20
May 19, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$17→$22
May 8, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$17→$18
May 8, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$18→$20
Mar 24, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$15→$17
Jan 28, 2026	Piper Sandler	David Amsellem	PT Raise	Neutral	$9→$12
Jan 16, 2026	Argus Research	—	Upgrade	Hold→Buy	$15
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$15
Oct 15, 2025	Truist Securities	Srikripa Devarakonda	Initiate	Buy	$15
Jun 6, 2025	Goldman Sachs	Matt Dellatorre	Initiate	Neutral	$10
Mar 7, 2025	Jefferies	Glen Santangelo	PT Cut	Buy	$15→$13
Mar 5, 2025	Piper Sandler	David Amsellem	PT Cut	Neutral	$14→$10
Feb 28, 2025	Barclays	Balaji Prasad	PT Cut	Underweight	$12→$9
Feb 28, 2025	B of A Securities	Jason Gerberry	PT Cut	Underperform	$11→$10

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $14

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20

JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Viatris, Raises Price Target to $26

UBS analyst Ashwani Verma maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $23 to $26.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Oppenheimer analyst Les Sulewski initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $25.

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.

Avi Kapoor

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.

Benzinga Newsdesk